each calendar year when ARVs prescribed), and any ART exposure at viral load test date. There is an error in the Author Contributions section. Carl Armon should be listed as the only author who
." Competing interests: We have the following interests: Rachel Hart and Carl Armon are employed by Cerner Corporation. There are no patents, products in development or marketed products to declare. This does ... , Thilakavathy Subramanian, Carl Armon, Stacey Purinton, Dana Franklin, Cheryl Akridge, Nabil Rayeed, Linda Battalora Cerner Corporation, Kansas City, MO; Frank J. Palella, Saira Jahangir, Conor Daniel Flaherty
, Centers for Disease Control and Prevention (CDC), Atlanta, Georgia; Harlen Hays, Kathleen C. Wood, Darlene Hankerson, Rachel Debes, Thilakavathy Subramanian, Carl Armon, Bonnie Dean, Dana Bryant Cerner ... the editors consider relevant to the content of the manuscript have been disclosed. Marcus D. Durham,1 Kate Buchacz,1 Carl Armon,2 Pragna Patel,1 Kathy Wood,2 and John T. Brooks1; for the HIV
Background. Traditional cardiovascular disease (CVD) risk factors, human immunodeficiency virus (HIV) infection, and antiretroviral (ARV) agents have been associated with CVD events in HIV-infected patients. We investigated the association of low CD4+ T lymphocyte cell count with incident CVD in a cohort of outpatients treated in 10 HIV specialty clinics in the United States...
Control and Prevention, Atlanta, GA); Kathleen C. Wood, Rose K. Baker, and Carl Armon (Cerner Corporation, Vienna, VA); Frank J. Palella, Joan S. Chmiel, Maria Deloria Knoll, Barbara Gillespie, and Erin